Nature Reviews Rheumatology Ревматология
Ianalumab reduces Sjögren disease activity
Аннотация
Nature Reviews Rheumatology, Published online: 10 November 2026; doi:10.1038/s41584-026-01466-3 In patients with active Sjögren disease, treatment with ianalumab 300 mg monthly reduced disease activity, but not symptom scores, more than placebo in two phase III clinical trials.